Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574560 | 0.90 | NPC1 (0.58) | RAB9APOLBNPC1MAOBCSF1R | |
| SCHEMBL15574712 | 0.89 | RAF1 (0.64) | P2RX3CSF1RRAF1EPHX2MAPK14 | |
| SCHEMBL16990647 | 0.85 | RAB9A (0.52) | RAB9AP2RX3CSF1RRAF1EPHX2 | |
| SCHEMBL16990602 | 0.85 | MEN1 (0.50) | RAB9ANPC1P2RX3NAMPTMAPK14 | |
| SCHEMBL15575210 | 0.85 | NAMPT (0.51) | RAB9APOLBNPC1P2RX3CSF1R | |
| SCHEMBL16990674 | 0.84 | KDR (0.47) | RAB9ANPC1P2RX3NAMPTRAF1 | |
| SCHEMBL15573250 | 0.84 | NAMPT (0.67) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL15574258 | 0.83 | NAMPT (0.59) | RAB9ANPC1NAMPTSMN1; SMN2RAF1 | |
| SCHEMBL16990598 | 0.83 | MEN1 (0.52) | RAB9APOLBNPC1P2RX3NAMPT | |
| SCHEMBL16990607 | 0.83 | MEN1 (0.53) | P2RX3CSF1RRAF1EPHX2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | RAB9A 3723/4885POLB 3563/4885NPC1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.